We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sphere Medical | LSE:SPHR | London | Ordinary Share | GB00B551W951 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.40 | 0.35 | 0.45 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/5/2018 08:20 | Funny how a few months ago no-one would touch us with a bargepole yet now were told new investors are queuing up to lend....go figure.As I said before well managed. W should become a theatre & stage impressario! | johnlewis79 | |
01/5/2018 08:33 | June '16 150 connections.. Dec'17 200...that's progress for you! | johnlewis79 | |
01/5/2018 06:05 | £9.6m loss....look out 200 connections! Boy this Co is going nowhere fast. Thats the AR in a nutshell Enjoy reading the other 50 pages of auditors report and notes to the financials! Development of P going well...ffs! No outlook, no lactate, no automation, no FDA, keep up the good work. Just as well I've written this one off... | johnlewis79 | |
30/4/2018 17:22 | Pathetic! And they want more money!.Not a chance! | johnlewis79 | |
27/4/2018 05:02 | Hi Del...commiserations on the baggies pp performance this season mind you i thought we'd be joining you at one stage! They state the nos will be out in April gives them till Monday or maybe even on Sat/Sun who knows. My point why give a date to investors if you have no intention of keeping to it? I really worry why I get so het up with Sphere when I know in my heart of hearts the news will for sure be unreservedly bad. If by some miracle I'm wrong then you'll know this was staged managed by you know who! | johnlewis79 | |
26/4/2018 13:45 | Correct DD. They can produce up to 8 months after year end....perhaps even longer.... | del44 | |
26/4/2018 10:45 | They have until September 18 according to companies house for 2017 FY | dusseldorf | |
26/4/2018 05:55 | Well it's either today or Monday or June or July.... or sod it.There must be some legal requirement into filing accounts but I'm sure I've read of firms filing nos years late. Don't expect that here as 1 + 1 = Don't take an accountant to work out as Sphere's nos are of that magnitude. | johnlewis79 | |
24/4/2018 07:25 | WPCT annual report out this morning..... Don't ask! | johnlewis79 | |
23/4/2018 17:18 | WPCT tanks 10% on Prothena failing to meet its primary endpoint trial..they have stopped all spending on the drug. Shares fell c.70% Another duster for W. | johnlewis79 | |
17/4/2018 11:25 | That's a very surprising article. Study is at QEH Birmigham where they did the initial trials on P3 years ago with Tom Clutton-Brock who used to be on Sphere board but resigned. This from Nov 17 Dr Tom Clutton-Brock is the clinical director of the new Medical Devices Testing and Evaluation Centre (MD-TEC), based in the Institute of Translational Medicine (ITM) in Birmingham. He was also recently named as one of the “100 most influential drivers of the health technology revolution, globally”. MTI finds out more about his work and MD-TEC. So, based on this and the picture in the article which shows P4 I'd say this is new news. However, the business case part surprises me. I'd say that is for QEH only. Sphere still on a knife edge though - cash burn vs delivery. | cc2014 | |
17/4/2018 09:57 | So they have become a research co again. What's the bloody point of dealing with the NHS when there never going to buy P off us? | johnlewis79 | |
16/4/2018 23:05 | Not sure if this is old news or not (starws, clutching) - the centre was only created in Dec17/Jan18 - so I'm not sure how this case study could have been done prior to the beginning of this year?Says they are creating a case study for it's use in the NHS:http://www.traum | dusseldorf | |
13/4/2018 09:25 | I would be surprised if they had 250k in the kitty. | johnlewis79 | |
12/4/2018 15:25 | how long before they've blown the £5m. Another 6 months? | cc2014 | |
12/4/2018 06:50 | Trying to maintain a positive attitude given past history with this Co is very hard. At the de-listing and W funding surely he must have had some assurances that Sphere would make it? I doubt he'd bung another £4m on the off chance we would sell a few more sensors.If he did he's a bigger mug than me. So doubting that I hold on very slim hopes but am resigned that I've done me money. | johnlewis79 | |
11/4/2018 19:26 | I'd love to know what all the staff do and get paid. From the outside it appears very top heavy (obscene 'admin' overheads) for a small Ltd company with essentially one product, no sales. Perhaps Woodford could force a sale, maybe that's what he's lining up all along, as I doubt the board can convince him to open his wallet again(!). Would be bizarre to invest £4m without a get out of jail plan. Either way, the situation looks precarious as time progresses with no updates. I've these valued at 0, but I effectively did that on the day prior to delist. I still think an all out disposal is on the cards, it's really the only reason I bought in. | dusseldorf | |
11/4/2018 17:18 | Dr David Roy Martyr terminated as Director. He was non-exec Chair. Some cost savings? | cc2014 | |
11/4/2018 16:09 | The website is back and nothing has changed, somewhat disappointing. | dusseldorf | |
11/4/2018 13:13 | Curtains closed , yet no ones in , end of a chapter then the full stop , you can't buy Proxima at your local shop , so heed my advice and don't get ill for there's little money in NHS till , broken and beaten the PIS sob little hope at our age of getting a job . | cellis94 | |
11/4/2018 07:47 | Results delayed....site taken down....you know what's coming next!! | johnlewis79 | |
11/4/2018 07:19 | Co site been taken down...hmm? All part of the FU to pis.... | johnlewis79 |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions